Dr Evelyn Harder, MD | |
4101 S. 4th St., Trafficway, Dept Of Anesthesiology, Leavenworth, KS 66048 | |
(913) 682-2000 | |
Not Available |
Full Name | Dr Evelyn Harder |
---|---|
Gender | Female |
Speciality | Anesthesiology |
Location | 4101 S. 4th St., Trafficway, Leavenworth, Kansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1114917069 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | MD.203341 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Evelyn Harder, MD 4101 S. 4th St., Trafficway, Dept Of Anesthesiology, Leavenworth, KS 66048 Ph: () - | Dr Evelyn Harder, MD 4101 S. 4th St., Trafficway, Dept Of Anesthesiology, Leavenworth, KS 66048 Ph: (913) 682-2000 |
News Archive
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji Kumar, MD, of Mayo Clinic, is open for enrollment at Mayo Clinic (Rochester, Minn.), City of Hope Cancer Center (Duarte, Calif.) and the University of Chicago (Chicago, Ill).
Curemark Founder and CEO Dr. Joan Fallon delivered the Industry Keynote address at the Third International Epigenomics, Sequencing 2009 Conference at Harvard Medical School on July 14th
Galderma today released the findings of a global survey highlighting the need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea and ways in which they can work together to achieve ‘clear' (IGA 0) skin.
FDA on Tuesday released draft guidelines that assert the agency's authority for regulating gene- and protein-based diagnostic tests for conditions such as breast cancer and ovarian cancer, the Wall Street Journal reports.
› Verified 2 days ago